CN101133064B - 取代的氧杂-二氮杂-螺-[5.5]-十一烷酮衍生物及其作为神经激肽拮抗剂的应用 - Google Patents
取代的氧杂-二氮杂-螺-[5.5]-十一烷酮衍生物及其作为神经激肽拮抗剂的应用 Download PDFInfo
- Publication number
- CN101133064B CN101133064B CN2006800066125A CN200680006612A CN101133064B CN 101133064 B CN101133064 B CN 101133064B CN 2006800066125 A CN2006800066125 A CN 2006800066125A CN 200680006612 A CN200680006612 A CN 200680006612A CN 101133064 B CN101133064 B CN 101133064B
- Authority
- CN
- China
- Prior art keywords
- alkyl
- compound
- formula
- base
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- OZLYREUCXXDFKX-GTTJCHINSA-N C1C2C3[C@H]1C1C2C1CC3 Chemical compound C1C2C3[C@H]1C1C2C1CC3 OZLYREUCXXDFKX-GTTJCHINSA-N 0.000 description 1
- XRXIWDQWESAWFN-UHFFFAOYSA-N O=C(c1cc(C(F)(F)F)cc(C(F)(F)F)c1)N(CC1)C(Cc2ccccc2)CC1N(CCC1(CCN(Cc2ccccc2)CC1)O1)C1=O Chemical compound O=C(c1cc(C(F)(F)F)cc(C(F)(F)F)c1)N(CC1)C(Cc2ccccc2)CC1N(CCC1(CCN(Cc2ccccc2)CC1)O1)C1=O XRXIWDQWESAWFN-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nanotechnology (AREA)
- Pulmonology (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05101657.4 | 2005-03-03 | ||
EP05101657 | 2005-03-03 | ||
PCT/EP2006/060419 WO2006094934A1 (en) | 2005-03-03 | 2006-03-03 | Substituted oxa-diaza-spiro-[5.5]-undecanone derivatives and their use as neurokinin antagonists |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101133064A CN101133064A (zh) | 2008-02-27 |
CN101133064B true CN101133064B (zh) | 2011-02-23 |
Family
ID=34938877
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2006800066125A Expired - Fee Related CN101133064B (zh) | 2005-03-03 | 2006-03-03 | 取代的氧杂-二氮杂-螺-[5.5]-十一烷酮衍生物及其作为神经激肽拮抗剂的应用 |
Country Status (15)
Country | Link |
---|---|
US (1) | US8138334B2 (ru) |
EP (1) | EP1874783B1 (ru) |
JP (1) | JP5094422B2 (ru) |
KR (1) | KR101355064B1 (ru) |
CN (1) | CN101133064B (ru) |
AT (1) | ATE469159T1 (ru) |
AU (1) | AU2006222061B2 (ru) |
BR (1) | BRPI0608074A2 (ru) |
CA (1) | CA2598530C (ru) |
DE (1) | DE602006014531D1 (ru) |
EA (1) | EA012421B1 (ru) |
ES (1) | ES2346147T3 (ru) |
MX (1) | MX2007010728A (ru) |
NZ (1) | NZ556629A (ru) |
WO (1) | WO2006094934A1 (ru) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
WO2011092293A2 (en) | 2010-02-01 | 2011-08-04 | Novartis Ag | Cyclohexyl amide derivatives as crf receptor antagonists |
JP2013518085A (ja) | 2010-02-01 | 2013-05-20 | ノバルティス アーゲー | CRF−1受容体アンタゴニストとしてのピラゾロ[5,1b]オキサゾール誘導体 |
WO2011095450A1 (en) | 2010-02-02 | 2011-08-11 | Novartis Ag | Cyclohexyl amide derivatives as crf receptor antagonists |
WO2015200594A2 (en) | 2014-06-25 | 2015-12-30 | Emory University | Methods of managing conditioned fear with neurokinin receptor antagonists |
KR101579688B1 (ko) | 2014-07-08 | 2015-12-24 | 재단법인 전남생물산업진흥원 | 좁쌀풀 추출물을 유효성분으로 함유하는 과민성 대장증후군에 의한 내장 통증 억제예방 또는 치료용 약학 조성물 |
US11458129B2 (en) | 2017-11-02 | 2022-10-04 | California Institute Of Technology | Neurokinin antagonists and uses thereof |
WO2020048827A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | 1, 3, 9-triazaspiro[5.5] undecan-2-one compounds |
WO2020048826A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | 5-substituted 1-oxa-3,9-diazaspiro[5.5]undecan-2-one compounds |
WO2020048828A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Pharma Aktiengesellschaft | 5-heteroaryl-3,9-diazaspiro[5.5]undecane compounds |
US20230346792A1 (en) * | 2020-07-18 | 2023-11-02 | Hoth Therapeutics, Inc. | Compositions and methods for treating lung inflammation |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1507449A (zh) * | 2001-05-14 | 2004-06-23 | - | 1-氧杂-3,9-二氮杂-螺[5.5]十一-2-酮衍生物及其作为神经激肽受体拮抗剂的用途 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5403593A (en) | 1991-03-04 | 1995-04-04 | Sandoz Ltd. | Melt granulated compositions for preparing sustained release dosage forms |
GB9109862D0 (en) | 1991-05-08 | 1991-07-03 | Beecham Lab Sa | Pharmaceutical formulations |
TW531537B (en) * | 1995-12-27 | 2003-05-11 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives |
TW382017B (en) | 1995-12-27 | 2000-02-11 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4-(fused imidazole)-piperidine derivatives |
TW429256B (en) | 1995-12-27 | 2001-04-11 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4-(benzimidazolyl- and imidazopyridinyl)-piperidine derivatives |
TR200000529T2 (tr) | 1997-08-29 | 2000-08-21 | Dsm N.V. | İçinde eksipiyan olmayan granüller |
US6482829B2 (en) * | 2000-06-08 | 2002-11-19 | Hoffmann-La Roche Inc. | Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor |
US7074794B2 (en) * | 2000-08-10 | 2006-07-11 | Mitsubishi Pharma Corporation | Proline derivatives and the use thereof as drugs |
DE60236206D1 (de) * | 2001-12-28 | 2010-06-10 | Acadia Pharm Inc | Spiroazacyclische verbindungen als monoaminrezeptormodulatoren |
MY141736A (en) * | 2002-10-08 | 2010-06-15 | Elanco Animal Health Ireland | Substituted 1,4-di-piperidin-4-yi-piperazine derivatives and their use as neurokinin antagonists |
CN1822828A (zh) * | 2003-06-10 | 2006-08-23 | 詹森药业有限公司 | 用于以阿片类药物为基础治疗疼痛的含取代的1,4-二哌啶-4-基哌嗪衍生物的新颖制剂 |
BRPI0507586A (pt) * | 2004-02-10 | 2007-07-03 | Hoffmann La Roche | moduladores de receptor de quimiocina ccr5 |
-
2006
- 2006-03-03 AU AU2006222061A patent/AU2006222061B2/en not_active Ceased
- 2006-03-03 NZ NZ556629A patent/NZ556629A/en not_active IP Right Cessation
- 2006-03-03 ES ES06708618T patent/ES2346147T3/es active Active
- 2006-03-03 DE DE602006014531T patent/DE602006014531D1/de active Active
- 2006-03-03 CA CA2598530A patent/CA2598530C/en not_active Expired - Fee Related
- 2006-03-03 EP EP06708618A patent/EP1874783B1/en active Active
- 2006-03-03 BR BRPI0608074-0A patent/BRPI0608074A2/pt not_active IP Right Cessation
- 2006-03-03 US US11/913,890 patent/US8138334B2/en not_active Expired - Fee Related
- 2006-03-03 WO PCT/EP2006/060419 patent/WO2006094934A1/en active Application Filing
- 2006-03-03 JP JP2007557517A patent/JP5094422B2/ja not_active Expired - Fee Related
- 2006-03-03 AT AT06708618T patent/ATE469159T1/de not_active IP Right Cessation
- 2006-03-03 MX MX2007010728A patent/MX2007010728A/es active IP Right Grant
- 2006-03-03 CN CN2006800066125A patent/CN101133064B/zh not_active Expired - Fee Related
- 2006-03-03 KR KR1020077020930A patent/KR101355064B1/ko not_active IP Right Cessation
- 2006-03-03 EA EA200701879A patent/EA012421B1/ru not_active IP Right Cessation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1507449A (zh) * | 2001-05-14 | 2004-06-23 | - | 1-氧杂-3,9-二氮杂-螺[5.5]十一-2-酮衍生物及其作为神经激肽受体拮抗剂的用途 |
Also Published As
Publication number | Publication date |
---|---|
WO2006094934A1 (en) | 2006-09-14 |
AU2006222061B2 (en) | 2011-04-28 |
JP5094422B2 (ja) | 2012-12-12 |
ES2346147T3 (es) | 2010-10-11 |
ATE469159T1 (de) | 2010-06-15 |
EA200701879A1 (ru) | 2008-02-28 |
DE602006014531D1 (de) | 2010-07-08 |
EP1874783A1 (en) | 2008-01-09 |
US8138334B2 (en) | 2012-03-20 |
BRPI0608074A2 (pt) | 2009-11-03 |
WO2006094934A8 (en) | 2006-12-07 |
CA2598530C (en) | 2014-12-16 |
KR20070113224A (ko) | 2007-11-28 |
CN101133064A (zh) | 2008-02-27 |
NZ556629A (en) | 2010-04-30 |
MX2007010728A (es) | 2007-10-12 |
AU2006222061A1 (en) | 2006-09-14 |
JP2008531659A (ja) | 2008-08-14 |
CA2598530A1 (en) | 2006-09-14 |
EP1874783B1 (en) | 2010-05-26 |
KR101355064B1 (ko) | 2014-01-24 |
EA012421B1 (ru) | 2009-10-30 |
US20100292228A1 (en) | 2010-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100591682C (zh) | 取代的二氮杂-螺-[4.5]-癸烷衍生物及其作为神经激肽拮抗剂的应用 | |
CN100584843C (zh) | 取代的二氮杂-螺-[5.5]-十一烷衍生物及其作为神经激肽拮抗剂的应用 | |
CN101133064B (zh) | 取代的氧杂-二氮杂-螺-[5.5]-十一烷酮衍生物及其作为神经激肽拮抗剂的应用 | |
CN1938291B (zh) | 被取代的4-烷基-和4-烷酰基-哌啶衍生物和其作为神经激肽拮抗剂的用途 | |
TWI329109B (en) | Substituted 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives and their use as neurokinin antagonists | |
JP4660199B2 (ja) | 置換1−ピペリジン−4−イル−4−アゼチジン−3−イル−ピペラジン誘導体およびそれらのニューロキニン拮抗薬としての使用 | |
CN101137657B (zh) | 作为神经激肽(nk1)拮抗剂的二氮杂-螺-[4.4]-壬烷衍生物 | |
CN100482229C (zh) | 取代的1-哌啶-3-基-4-哌啶-4-基-哌嗪衍生物及其作为神经激肽拮抗剂的用途 | |
ES2310260T3 (es) | Derivados sustituidos de 4-(4-piperidin-4-il-piperazin-1-il)-azepan y su uso como antagonistas de la neuroquinina. | |
CN100577643C (zh) | 取代的1,4-二-哌啶-4-基-哌嗪衍生物及其用于制备神经激肽拮抗剂的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110223 Termination date: 20160303 |